Granix (Filgrastim)

Generic Name

Filgrastim

Brand Names

Granix, Neupogen, Nivestym, Nypozi, NYPOZI txid, Releuko, Zarxio

FDA approval date: April 07, 1997

Classification: Leukocyte Growth Factor

Form: Injection

What is Granix (Filgrastim)?

GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. GRANIX is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Procedure, Drug, Biological

Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic hematopoietic stem cell transplantation. ASTX727 is a combination of cedazuridine and decitabine. Ce...

Who is this study for: Child to adult patients with Severe Aplastic Anemia

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Device, Biological

Study Drug: Cordin

Study Phase: Phase 1/Phase 2

Background: Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant. Researchers are testing ways to make stem cell transplant safer and more effective.

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells

Who is this study for: Child to adult patients with Severe Aplastic Anemia

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Device, Other

Study Drugs: Granulocyte Colony-Stimulating Factor, Peripheral Blood Cell Infusion

Study Phase: Phase 2

Background: * Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia. Allogenic stem cell transplants encourage the growth of new bone marrow to replace that of the recipient. Because stem cell transplants can have serious complications, researchers are interested in developing n...

View All Clinical Trials